Google
TECH 株価分析 — BIO-TECHNE CORP (Healthcare >> Biotechnology)
TECH に関するよくある質問
TECHのPER（株価収益率）は？
BIO-TECHNE CORP（TECH）は現在PER 88.20倍で取引されています。
TECHのROE（自己資本利益率）は？
BIO-TECHNE CORPのROEは5.25%です。
TECHの配当利回りは？
BIO-TECHNE CORPの配当利回りは0.44%です。
TECHの品質スコア（Quality Score）は？
当社のAIはTECHの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
TECHは今が買い時ですか？
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
TECHはどのセクターに属しますか？
BIO-TECHNE CORPはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
TECH AI Analysis Summary
Our AI summary for TECH: BIO-TECHNE CORP (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 88.20, ROE of 5.25%, a dividend yield of 0.44%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 72.09
Price
0.06
(0.08%)
Day Change
|
|
|---|
TECH, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
2775
|
| Magic Formula Rank by ROE |
2775
|
| Magic Formula Rank by ROIC |
2875
|
| Price | 72.09 |
| PBV / Sector |
5.38 / 5.20
|
| Earning Per Share | 0.70 |
| PE / Sector |
88.20 / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
277.83 M
GREAT
|
| Average 1W Daily Value |
373.69 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
58% |
| 配当 |
|
12% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:34 |
| Symbol | TECH |
| Name | BIO-TECHNE CORP |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 155.81 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 11,223.04 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 614 McKinley Place N.E., Minneapolis, MN, United States, 55413
Phone: 612 379 8854
Website: https://www.bio-techne.com
Employees: 3,100
Sector: Healthcare >> Biotechnology
Description: Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
